Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06003387
Other study ID # CSL222_3005
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 30, 2024
Est. completion date October 2028

Study information

Verified date May 2024
Source CSL Behring
Contact Trial Registration Coordinator
Phone 1-610-878-4000
Email clinicaltrials@cslbehring.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date October 2028
Est. primary completion date October 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has congenital hemophilia B with known severe or moderately severe FIX deficiency (= 2% of normal circulating FIX) for which the participant is on continuous routine FIX prophylaxis - Has 2 consecutive detectable AAV5 NAb titer results between Screening and Visit L-Final using a validated AAV5 NAb assay (based on central laboratory results) - Has > 150 previous exposure days to FIX replacement therapy - Has been on stable FIX prophylaxis for at least 2 months before Screening - Has demonstrated capability to independently, accurately, and in a timely manner complete the eDiary during the Lead-in Period, as judged by the investigator - Acceptance to barrier contraception protection for 1 year starting the day of CSL222 treatment - Able to provide informed consent after receipt of verbal and written information about the study - Investigator believes that the participant (or the participant's legally acceptable representative[s]) understands the nature, scope, and possible consequences of the study and is able to adhere to the study procedures. Exclusion Criteria: - History of FIX inhibitors or positive FIX inhibitor test at Screening or Visit L (lead-in period)-Final (based on central laboratory results) - Screening and Visit L-Final laboratory values that meet the definition of Severe Hepatic Impairment per Common Terminology Criteria for Adverse Events (CTCAE) (based on central laboratory results) - ALT > 2 × the upper limit of normal (ULN) at Screening and Visit L-Final (based on central laboratory results) - Any condition other than hemophilia B resulting in an increased bleeding tendency - Any uncontrolled or untreated infection (human immunodeficiency virus [HIV], hepatitis C, etc.) or any other significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with adherence to the clinical study protocol or with the degree of tolerance to CSL222. - Thrombocytopenia, defined as a platelet count below 50 × 10^9/L, at Screening and Visit L-Final (based on central laboratory results) - Known history of allergy to corticosteroids or known medical condition that would require chronic administration of steroids. - Known uncontrolled allergic conditions or allergy / hypersensitivity to any component of the CSL222 excipients - Previous gene therapy treatment - Receipt of an experimental agent or device within 60 days before Screening until the end of the study. - Note: Other protocol pre-specified exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
CSL222 (AAV5-hFIXco-Padua)
Administered as a single IV infusion.

Locations

Country Name City State
Canada McMaster University - Hamilton - 12400017 Hamilton Ontario
Israel Sheba Medical Center - 37600004 Tel Hashomer
United States University of Michigan - 84000285 Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
CSL Behring

Countries where clinical trial is conducted

United States,  Canada,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annualized Bleeding Rate (ABR) The total, spontaneous, joint, and Factor IX (FIX)-treated bleeding episodes will be analyzed. ABR is calculated as the total bleeding episodes divided by the total time at risk. Post-dose: Months 7 to 18
Secondary Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (TESAEs), and TEAEs of Special Interest (TEAESIs) Post-dose: At Months 6,12, and 18
Secondary Percentage of Participants With TEAEs, TESAEs, and TEAESIs Post-dose: At Months 6,12, and 18
Secondary Number of TEAEs, TESAEs, and TEAESIs Post-dose: At Months 6,12, and 18
Secondary Number of Participants with Change From Baseline in Abdominal Ultrasound Baseline up to 18 months post dose
Secondary Number of Participants Who Develop Factor IX (FIX) Inhibitors Up to 18 months post dose
Secondary Percentage of Participants who Develop FIX Inhibitors Up to 18 months post dose
Secondary Number of Participants with Clinically Significant Hematology and Serum Chemistry Parameters Up to 18 months post dose
Secondary Percentage of Participants With Clinically Significant Hematology and Serum Chemistry Parameters Up to 18 months post dose
Secondary Number of Participants with Clinically Significant Change in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Up to 18 months post dose
Secondary Percentage of Participants With Clinically Significant Change in ALT or AST Up to 18 months post dose
Secondary Number of Participants Treated With Corticosteroids For Change in ALT or AST Up to 18 months post dose
Secondary Percentage of Participants Treated With Corticosteroids For Change in ALT or AST Up to 18 months post dose
Secondary Number of Participants With Clinically Significant Alpha-fetoprotein (AFP) Up to 18 months post dose
Secondary Percentage of Participants With Clinically Significant AFP Up to 18 months post dose
Secondary Number of Participants with Infusion Related Reactions or Hypersensitivity Reactions Up to 18 months post dose
Secondary Percentage of Participants With Infusion Related Reactions or Hypersensitivity Reactions Up to 18 months post dose
Secondary Number of Participants With the Endogenous FIX Activity Post-dose: At Months 6, 12, and 18
Secondary Change From Baseline in the Endogenous FIX Activity Baseline up to Months 6, 12, and 18 post dose
Secondary Annualized Consumption of FIX Replacement Therapy Post-dose: Months 7 to 18
Secondary Annualized Infusion Rate of FIX Replacement Therapy Post-dose: Months 7 to 18
Secondary Percentage of Participants Remaining Free of Previous Continuous Routine FIX Prophylaxis Post-dose: Months 7 to 18
Secondary ABR for Spontaneous Bleeding Episodes, Joint Bleeding Episodes, and FIX-treated Bleeding Episodes Separately Post-dose: Months 7 to 18
Secondary Correlation Analysis of FIX Activity Levels Post-dose: Months 6 to 18
Secondary Number of Participants With New Target Joints and Resolved New or Preexisting Target Joints Target joint is defined as 3 or more spontaneous bleeding episodes into a single joint. Post-dose: Months 7 to 18
Secondary Number of Participants With Zero Bleeds Following Stable FIX Expression Post-dose: Months 7 to 18
Secondary Percentage of Participants With Zero Bleeds Following Stable FIX Expression Post-dose: Months 7 to 18
Secondary Hemophilia Quality of Life Questionnaire (Hem-A-QoL) Total Score and Treatment Domain Score The Hem-A-QoL (Hemophilia Quality of Life Questionnaire for Adults) consists of 46 items comprising 10 domains: physical health, feelings, treatment, work and school, dealing with hemophilia, family planning, future, partnerships and sexuality, sports and leisure, and view of yourself for which responses will be recorded from 5 options (never, seldom, sometimes, often, and always; for some items, there is also a "not applicable" option). The Hem-A-QoL Total Score and Treatment Domain Score range from 0 to 100, with lower scores reflecting a better quality of life. Post-dose: Months 6 to 18
Secondary Change From Baseline in the Hem-A-QoL Total Score and Treatment Domain Score The Hem-A-QoL consists of 46 items comprising 10 domains: physical health, feelings, treatment, work and school, dealing with hemophilia, family planning, future, partnerships and sexuality, sports and leisure, and view of yourself for which responses will be recorded from 5 options (never, seldom, sometimes, often, and always; for some items, there is also a "not applicable" option). The Hem-A-QoL Total Score and Treatment Domain Score range from 0 to 100, with lower scores reflecting a better quality of life. The change from baseline in the Hem-A-QoL Total Score and Treatment Domain Score will be determined. Baseline, Months 6 to 18 post dose
Secondary EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Overall Score The EQ-5D-5L questionnaire visual analogue scale (VAS) measures overall health status on a vertical VAS ranging from 0 to 100. A higher score indicates better quality of life. Post-dose: Months 6 to 18
Secondary EQ-5D-5L Index Scores The EQ-5D-5L questionnaire descriptive system of health-related quality of life consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which responses will be recorded on 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The responses will be converted into a single index utility score (typically between -0.6 and 1). A higher score indicates better quality of life. Post-dose: Months 6 to 18
Secondary Change from Baseline in the EQ-5D-5L VAS Score The EQ-5D-5L questionnaire visual analogue scale (VAS) measures overall health status on a vertical VAS ranging from 0 to 100. A higher score indicates better quality of life. The change from baseline in the EQ-5D-5L VAS score will be determined. Baseline, Months 6 to 18 post dose
Secondary Change From Baseline in the EQ-5D-5L Index Scores The EQ-5D-5L questionnaire descriptive system of health-related quality of life consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which responses will be recorded on 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The responses will be converted into a single index utility score (typically between -0.6 and 1). A higher score indicates better quality of life. The change from baseline in the EQ-5D-5L index score will be determined. Baseline, Months 6 to 18 post dose
See also
  Status Clinical Trial Phase
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01662531 - A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B Phase 3
Completed NCT01335061 - Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B Phase 3
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Completed NCT00037557 - Study Evaluating rFIX; BeneFIX in Severe Hemophilia B Phase 3
Completed NCT02554773 - An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B Phase 1/Phase 2
Terminated NCT02807753 - The Hemophilia Ultrasound Project
Active, not recruiting NCT03901755 - An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Not yet recruiting NCT05980377 - Patterns of Hemophilia Care in Assiut Children Patients
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03248141 - Understanding Hemophilia A and B Drug Dosage Administration Patterns
Terminated NCT01460147 - Osteoporosis and MRI Study in Hemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Completed NCT02571569 - A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors Phase 1
Terminated NCT01620801 - Hemophilia B Gene Therapy With AAV8 Vector Phase 1
Completed NCT01233440 - Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B Phase 1
Active, not recruiting NCT04135300 - Gene Therapy for Chinese Hemophilia B N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Terminated NCT00947193 - Study of Ataluren (PTC124) in Hemophilia A and B Phase 2